New York: Inovio Pharmaceuticals (NASDAQ:INO) Stock Has Just Had Its “Buy” Rating Reiterated by H.C. Wainwright. Shares now Have a $13.0 Target

December 7, 2017 - By Dolores Ford

 New York: Inovio Pharmaceuticals (NASDAQ:INO) Stock Has Just Had Its

Inovio Pharmaceuticals (NASDAQ:INO) Rating Reaffirmed

H.C. Wainwright now has a $13.0 target on shares of Inovio Pharmaceuticals (NASDAQ:INO). The target indicates a potential upside of 196.80 % from the current stock price of Inovio Pharmaceuticals (NASDAQ:INO). This rating was revealed to clients and investors in an analyst report on Friday, 6 October.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Ratings Coverage

Among 8 analysts covering Inovio Pharmaceuticals (NASDAQ:INO), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Inovio Pharmaceuticals has $31 highest and $9 lowest target. $14.33’s average target is 227.17% above currents $4.38 stock price. Inovio Pharmaceuticals had 34 analyst reports since August 10, 2015 according to SRatingsIntel. The stock has “Neutral” rating by PiperJaffray on Thursday, March 16. The company was maintained on Friday, September 22 by H.C. Wainwright. Stifel Nicolaus maintained Inovio Pharmaceuticals, Inc. (NASDAQ:INO) on Thursday, October 5 with “Buy” rating. The rating was maintained by H.C. Wainwright with “Buy” on Thursday, June 8. The company was downgraded on Tuesday, August 9 by Maxim Group. Zacks downgraded Inovio Pharmaceuticals, Inc. (NASDAQ:INO) on Wednesday, August 12 to “Hold” rating. Stifel Nicolaus maintained the shares of INO in report on Monday, June 26 with “Buy” rating. H.C. Wainwright maintained the stock with “Buy” rating in Friday, July 7 report. Maxim Group maintained Inovio Pharmaceuticals, Inc. (NASDAQ:INO) on Tuesday, January 5 with “Buy” rating. The rating was maintained by H.C. Wainwright on Thursday, November 9 with “Buy”.

It closed at $4.38 lastly. It is down 29.01% since December 7, 2016 and is downtrending. It has underperformed by 45.71% the S&P500.

Analysts await Inovio Pharmaceuticals, Inc. (NASDAQ:INO) to report earnings on March, 21. They expect $-0.29 EPS, up 19.44 % or $0.07 from last year’s $-0.36 per share. After $-0.40 actual EPS reported by Inovio Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -27.50 % EPS growth.

Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. The company has market cap of $395.50 million. The Company’s SynCon immunotherapy design has the ability to break the immune systemÂ’s tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It currently has negative earnings. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, Ebola, Middle East Respiratory Syndrome, and Zika virus.

More recent Inovio Pharmaceuticals, Inc. (NASDAQ:INO) news were published by: Globenewswire.com which released: “Inovio Pharmaceuticals SynCon® TERT Cancer Immunotherapy Combined with …” on November 27, 2017. Also Fool.com published the news titled: “Why Inovio Pharmaceuticals Inc. Is Sinking Today” on November 09, 2017. Globenewswire.com‘s news article titled: “Inovio Pharmaceuticals Appoints Wendy Yarno To its Board of Directors” with publication date: December 06, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.